364 related articles for article (PubMed ID: 34695229)
21. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
[TBL] [Abstract][Full Text] [Related]
22. Is a third SARS-CoV-2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
Spyridonidis A
Br J Haematol; 2023 Apr; 201(1):9-10. PubMed ID: 36477621
[TBL] [Abstract][Full Text] [Related]
23. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
[TBL] [Abstract][Full Text] [Related]
24. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
[TBL] [Abstract][Full Text] [Related]
25. Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.
Bankova AK; Pasin C; Huang A; Cicin-Sain C; Epp S; Audige A; Mueller NJ; Nilsson J; Vilinovszki O; Nair G; Wolfensberger N; Hockl P; Schanz U; Trkola A; Kouyos R; Hasse B; Zinkernagel AS; Manz MG; Abela IA; Müller AMS
Br J Haematol; 2023 Apr; 201(1):58-63. PubMed ID: 36382698
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre.
Chukwu CA; Mahmood K; Elmakki S; Gorton J; Kalra PA; Poulikakos D; Middleton R
PLoS One; 2022; 17(3):e0265130. PubMed ID: 35271655
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
[TBL] [Abstract][Full Text] [Related]
28. The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study.
Ngo D; Chen J; Tinajero J; Aribi A; Arslan S; Marcucci G; Nakamura R; Al Malki MM; Forman SJ; Dadwal S; Ali H
Stem Cell Res Ther; 2023 Apr; 14(1):95. PubMed ID: 37072867
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of mRNA1273 SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Single center experience.
Huguet M; Boigues M; Sorigué M; Blanco J; Quirant B; Ferrà C; ;
Med Clin (Barc); 2024 Apr; 162(7):313-320. PubMed ID: 38000941
[TBL] [Abstract][Full Text] [Related]
30. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
Wu X; Wang L; Shen L; He L; Tang K
J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
[TBL] [Abstract][Full Text] [Related]
31. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
[TBL] [Abstract][Full Text] [Related]
32. Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
Mori Y; Uchida N; Wake A; Miyawaki K; Eto T; Nakamura T; Iwasaki H; Ito Y; Tanimoto K; Katayama Y; Imamura Y; Takahashi T; Fujisaki T; Kamimura T; Choi I; Ishitsuka K; Yoshimoto G; Ogawa R; Sugita J; Takamatsu Y; Tanimoto K; Hidaka T; Miyamoto T; Akashi K; Nagafuji K
Vaccine; 2023 Nov; 41(47):6899-6903. PubMed ID: 37866994
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
Piñana JL; López-Corral L; Martino R; Vazquez L; Pérez A; Martin-Martin G; Gago B; Sanz-Linares G; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; Corona M; Marcos-Corrales S; Tormo M; Hernández-Rivas JÁ; Montoro J; Rodriguez-Fernandez A; Risco-Gálvez I; Rodríguez-Belenguer P; Hernandez-Boluda JC; García-Cadenas I; Ruiz-García M; Muñoz-Bellido JL; Solano C; Cedillo Á; Sureda A; Navarro D;
J Hematol Oncol; 2022 May; 15(1):54. PubMed ID: 35526045
[TBL] [Abstract][Full Text] [Related]
34. Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.
Meejun T; Srisurapanont K; Manothummetha K; Thongkam A; Mejun N; Chuleerarux N; Sanguankeo A; Phongkhun K; Leksuwankun S; Thanakitcharu J; Lerttiendamrong B; Langsiri N; Torvorapanit P; Worasilchai N; Plongla R; Hirankarn N; Nematollahi S; Permpalung N; Moonla C; Kates OS
Blood Adv; 2023 Sep; 7(18):5624-5636. PubMed ID: 37389818
[TBL] [Abstract][Full Text] [Related]
35. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
[TBL] [Abstract][Full Text] [Related]
36. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
37. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
Gao H; Wang J; Zheng X; Pei X; Zheng Y; Zhai W; Zhang R; Chen X; Ma Q; Wei J; Yang D; Pang A; He Y; Feng S; Cao Y; Jiang E
Front Cell Infect Microbiol; 2024; 14():1324019. PubMed ID: 38505288
[TBL] [Abstract][Full Text] [Related]
38. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
39. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.
Rubin M; Suelzer E; Ulschmid C; Thapa B; Szabo A; Bilal Abid M
Asian Pac J Cancer Prev; 2024 Feb; 25(2):393-399. PubMed ID: 38415523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
